[go: up one dir, main page]

CY1121546T1 - Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου - Google Patents

Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου

Info

Publication number
CY1121546T1
CY1121546T1 CY20191100414T CY191100414T CY1121546T1 CY 1121546 T1 CY1121546 T1 CY 1121546T1 CY 20191100414 T CY20191100414 T CY 20191100414T CY 191100414 T CY191100414 T CY 191100414T CY 1121546 T1 CY1121546 T1 CY 1121546T1
Authority
CY
Cyprus
Prior art keywords
humanized antibodies
themselves
antibodies against
cancer treatment
liv
Prior art date
Application number
CY20191100414T
Other languages
English (en)
Inventor
Maria Leia Smith
Django Sussman
William Arthur
Albina Nesterova
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of CY1121546T1 publication Critical patent/CY1121546T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η εφεύρεση παρέχει ανθρωποποιημένα αντισώματα που δεσμεύονται ειδικά με LIV-1. Τα αντισώματα είναι χρήσιμα για αγωγή και διαγνώσεις διαφόρων καρκίνων, όπως επίσης για ανίχνευση της LIV-1.
CY20191100414T 2010-12-06 2019-04-12 Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου CY1121546T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42029110P 2010-12-06 2010-12-06
US201161446990P 2011-02-25 2011-02-25
EP11847198.6A EP2648752B1 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer
PCT/US2011/063612 WO2012078688A2 (en) 2010-12-06 2011-12-06 Humanized antibodies to liv-1 and use of same to treat cancer

Publications (1)

Publication Number Publication Date
CY1121546T1 true CY1121546T1 (el) 2020-05-29

Family

ID=46207694

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100472T CY1118874T1 (el) 2010-12-06 2017-04-27 Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY20191100414T CY1121546T1 (el) 2010-12-06 2019-04-12 Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY20201101211T CY1123883T1 (el) 2010-12-06 2020-12-22 Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100472T CY1118874T1 (el) 2010-12-06 2017-04-27 Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201101211T CY1123883T1 (el) 2010-12-06 2020-12-22 Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου

Country Status (25)

Country Link
US (6) USRE48959E1 (el)
EP (4) EP3786185A1 (el)
JP (6) JP6105481B2 (el)
KR (5) KR101993921B1 (el)
CN (1) CN103533957B (el)
AU (4) AU2011338480B8 (el)
BR (2) BR122021020513B1 (el)
CA (2) CA3211246A1 (el)
CY (3) CY1118874T1 (el)
DK (3) DK2648752T3 (el)
ES (3) ES2719548T3 (el)
HR (1) HRP20170567T1 (el)
HU (3) HUE052806T2 (el)
IL (4) IL299837A (el)
LT (1) LT2648752T (el)
MX (3) MX351027B (el)
NZ (1) NZ611468A (el)
PL (3) PL3156420T3 (el)
PT (3) PT3156420T (el)
RS (1) RS55843B1 (el)
RU (1) RU2608646C2 (el)
SG (3) SG190938A1 (el)
SI (3) SI2648752T1 (el)
WO (1) WO2012078688A2 (el)
ZA (1) ZA201303803B (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101993921B1 (ko) 2010-12-06 2019-06-28 시애틀 지네틱스, 인크. Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014102299A2 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
JP2016526909A (ja) * 2013-07-31 2016-09-08 アムジエン・インコーポレーテツド Ｆｃ含有ポリペプチドの安定化
MX2021008464A (es) 2013-10-15 2023-03-03 Seattle Genetics Inc Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
KR20180107111A (ko) 2016-02-17 2018-10-01 시애틀 지네틱스, 인크. 암 및 면역학적 장애를 치료하기 위한 bcma 항체 및 이의 용도
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR20190038579A (ko) 2016-08-09 2019-04-08 시애틀 지네틱스, 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
EA201891851A1 (ru) * 2016-09-16 2019-04-30 Сиэтл Дженетикс, Инк. Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
JP2019530697A (ja) 2016-10-18 2019-10-24 シアトル ジェネティックス， インコーポレイテッド ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤の標的化送達
CN110612104A (zh) 2017-03-15 2019-12-24 希沃尔拜克治疗公司 苯并氮杂*化合物、缀合物及其用途
SG11201908325PA (en) 2017-03-24 2019-10-30 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11305224B2 (en) 2017-04-18 2022-04-19 3M Innovative Properties Company Air filter media with post-pleat-deposited sorbent particles
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
AU2018326877A1 (en) * 2017-09-02 2020-03-05 Abbvie Inc. Anti-EGFR antibody drug conjugates (ADC) and uses thereof
CN111295201A (zh) * 2017-09-02 2020-06-16 艾伯维公司 抗egfr抗体药物结合物（adc）和其用途
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3717518A1 (en) * 2017-12-01 2020-10-07 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
IL276546B2 (en) 2018-02-20 2024-08-01 Seagen Inc Hydrophobic auristatin F compounds and their conjugates
CN113164774A (zh) 2018-09-12 2021-07-23 希沃尔拜克治疗公司 Toll样受体激动剂的抗体缀合物
JP2022500404A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
CA3111784A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Methods and compositions for the treatment of disease with immune stimulatory conjugates
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
US20210292429A1 (en) * 2018-11-07 2021-09-23 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
WO2021016233A1 (en) * 2019-07-22 2021-01-28 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
JP2022544543A (ja) 2019-08-15 2022-10-19 シルバーバック セラピューティックス インコーポレイテッド ベンザゼピンコンジュゲートの製剤およびその使用
AU2020358726A1 (en) 2019-10-01 2022-04-07 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
CN115066259A (zh) 2019-12-09 2022-09-16 思进公司 使用liv1-adc和pd-1拮抗剂的组合疗法
BR112022012885A2 (pt) 2019-12-30 2022-09-06 Seagen Inc Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
CA3197158A1 (en) 2020-09-28 2022-03-31 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
TW202408586A (zh) 2022-05-12 2024-03-01 大陸商先聲再明醫藥有限公司 喜樹鹼類衍生物及配體-藥物偶聯物
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
WO2024165056A1 (en) 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies targeting liv-1 and uses thereof
WO2024188339A1 (zh) * 2023-03-15 2024-09-19 浙江博锐生物制药有限公司 抗liv-1抗体和抗liv-1抗体药物偶联物及其药物用途
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2132500A1 (en) 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
ATE364089T1 (de) 1996-10-31 2007-06-15 Abbott Lab Reagenzien und methoden zum nachweis von erkrankungen der brust
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
JP2001521744A (ja) 1997-10-31 2001-11-13 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
JP2001523472A (ja) 1997-11-18 2001-11-27 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
JP3422776B2 (ja) 1998-08-04 2003-06-30 ダイアデクスアス・インコーポレーテッド 乳癌を診断、監視、病期決定、造影及び治療する新規な方法
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
CA2395832A1 (en) 2000-01-25 2001-08-02 Genentech, Inc. Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
AU2001264099A1 (en) 2000-06-13 2001-12-24 University College Cardiff Consultants Ltd. Zinc transporters
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002324451A1 (en) 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1572087B1 (en) 2002-03-08 2008-05-14 PDL BioPharma, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
HUE027549T2 (hu) 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
JP2006520194A (ja) * 2003-01-27 2006-09-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｉｇｓｆ９およびｌｉｖ−１を使用して癌を処置するための組成物および方法
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR20050010267A (ko) 2003-07-18 2005-01-27 삼성전자주식회사 식각장치
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
KR101068289B1 (ko) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CA2621502A1 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
MX2008013121A (es) 2006-04-13 2009-03-25 Novartis Vaccines & Diagnostic Metodo para tratar, diagnosticar o detectar cancer.
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
WO2008131376A2 (en) 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20110195995A1 (en) 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
KR101993921B1 (ko) 2010-12-06 2019-06-28 시애틀 지네틱스, 인크. Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
WO2012125712A2 (en) 2011-03-14 2012-09-20 Respira Health, Llc Lung tumor classifier for current and former smokers
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
EP3717518A1 (en) 2017-12-01 2020-10-07 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
US20210292429A1 (en) 2018-11-07 2021-09-23 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent

Also Published As

Publication number Publication date
AU2011338480B8 (en) 2017-03-23
AU2021204473B2 (en) 2024-07-18
SI2648752T1 (sl) 2017-06-30
IL299837A (en) 2023-03-01
SI3156420T1 (sl) 2019-05-31
US20200165335A1 (en) 2020-05-28
KR20200145867A (ko) 2020-12-30
EP2648752A2 (en) 2013-10-16
SG190938A1 (en) 2013-07-31
PL2648752T3 (pl) 2017-07-31
CA2819038A1 (en) 2012-06-14
PL3156420T3 (pl) 2019-08-30
AU2011338480A1 (en) 2013-06-13
CY1123883T1 (el) 2022-03-24
CA2819038C (en) 2023-10-17
MX2020010639A (es) 2020-10-28
CN103533957A (zh) 2014-01-22
JP2019073515A (ja) 2019-05-16
CA3211246A1 (en) 2012-06-14
KR20230057485A (ko) 2023-04-28
AU2011338480A8 (en) 2017-03-23
JP2014506120A (ja) 2014-03-13
RS55843B1 (sr) 2017-08-31
SG10201510041QA (en) 2016-01-28
DK2648752T3 (en) 2017-03-27
JP6105481B2 (ja) 2017-03-29
KR20190076068A (ko) 2019-07-01
MX379481B (es) 2025-03-11
US20130259860A1 (en) 2013-10-03
AU2017203851A1 (en) 2017-06-22
EP3461847A1 (en) 2019-04-03
EP3156420B1 (en) 2019-02-20
JP6869218B2 (ja) 2021-05-12
PL3461847T3 (pl) 2021-07-05
DK3156420T3 (en) 2019-04-29
JP2021106599A (ja) 2021-07-29
MX351027B (es) 2017-09-28
SI3461847T1 (sl) 2021-03-31
JP2024178209A (ja) 2024-12-24
US20240247059A1 (en) 2024-07-25
BR122021020513B1 (pt) 2022-10-25
AU2017203851B2 (en) 2019-01-31
LT2648752T (lt) 2017-04-10
JP6453924B2 (ja) 2019-01-16
PT3461847T (pt) 2020-12-24
KR20130135884A (ko) 2013-12-11
KR20220011811A (ko) 2022-01-28
EP3461847A8 (en) 2021-04-14
RU2013130609A (ru) 2015-01-20
PT3156420T (pt) 2019-05-27
CN103533957B (zh) 2016-06-22
HUE031726T2 (en) 2017-07-28
US20180079810A1 (en) 2018-03-22
AU2019202530A1 (en) 2019-05-02
JP2017149717A (ja) 2017-08-31
JP7166384B2 (ja) 2022-11-07
US9783608B2 (en) 2017-10-10
HRP20170567T1 (hr) 2017-06-16
EP3786185A1 (en) 2021-03-03
DK3461847T3 (da) 2020-12-14
ES2620264T3 (es) 2017-06-28
IL226754B (en) 2018-10-31
NZ611468A (en) 2015-06-26
ZA201303803B (en) 2014-07-30
KR102198189B1 (ko) 2021-01-05
CY1118874T1 (el) 2018-01-10
WO2012078688A3 (en) 2012-08-23
KR101993921B1 (ko) 2019-06-28
RU2608646C2 (ru) 2017-01-23
MX2013006365A (es) 2013-08-15
EP3461847B1 (en) 2020-09-23
WO2012078688A2 (en) 2012-06-14
USRE48959E1 (en) 2022-03-08
EP2648752B1 (en) 2017-02-15
US9228026B2 (en) 2016-01-05
AU2011338480B2 (en) 2017-03-16
PT2648752T (pt) 2017-03-28
JP2023011709A (ja) 2023-01-24
IL261900A (en) 2018-10-31
AU2019202530B2 (en) 2021-04-01
HUE043355T2 (hu) 2019-08-28
ES2842895T3 (es) 2021-07-15
IL273607B2 (en) 2023-06-01
HUE052806T2 (hu) 2021-05-28
EP3156420A1 (en) 2017-04-19
SG10201912646UA (en) 2020-02-27
AU2021204473A1 (en) 2021-07-29
ES2719548T3 (es) 2019-07-11
US20160185858A1 (en) 2016-06-30
EP2648752A4 (en) 2015-05-20
BR112013013781A2 (pt) 2016-09-13
IL273607A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121663T1 (el) Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
CY1124849T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
EA201591801A1 (ru) Лекарственные конъюгаты антител
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1114458T1 (el) Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX377297B (es) Anticuerpos tem8 y su uso.
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201400991A1 (ru) Комбинированная терапия с использованием антител к человеческому csf-1r и ее применения
EA201201000A1 (ru) Способы лечения колоректального рака
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
CY1122156T1 (el) Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων
CY1116332T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΠΟΥ ΔΕΣΜΕΥΟΝΤΑΙ ME TGF-α ΚΑΙ ΕΠΙΡΕΓΟΥΛΙΝΗ
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.